Tongwei Successfully Developed Tilapia Streptococcus (oral) Vaccine

May, 29, Hainan Tongwei Organized Tilapia Cultivation and Disease Control Technology Forum. Assistant President of Tongwei Co., Ltd., General Manger of Hainan Tongwei, Yi Ganghui, Director of Tongwei Pharmaceuticals Research Institute Xiao Dan, Marketing Manager Hong Rui, Director of Tongwei Aquaculture Research Institute Mi Haifeng, officials from Wenchang Provincial Oceanic and Fishery Administration, as well as Hainan Tongwei dealers and farmers attended the forum.

At the forum, Ms. Xiao Dan and researcher Yang Tao made specific analysis on tilapia streptococcus agalactiae disease, and reported Tongwei’s latest research progress on this disease with an emphasis on related practical techniques of disease prevention at summer time. Ms. Xiao also introduced to the attendees oral immunization and control measures of tilapia streptococcus disease. According to research results, oral vaccine has a protection rate of over 60% for tilapia strain under median lethal dose. With the duration of immunity arrives at more than 4 months, it can generally guarantee the safety of tilapia from the streptococcus agalactiae peak from July to October.